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Abstract-Enzymes within the CYP3A subfamily are major Phase I drug-metabolizing enzymes present 
in hepatocytes and small bowel enterocytes. These enzymes are highly inducible in the liver by many 
structurally diverse compounds, including a number of commonly used medications. Studies indicate 
that CYP3A enzymes present in small bowel enterocytes are also inducible. However, the regulation of 
CYP3A enzymes in this tissue has not been well characterized, in part because in uivo studies are 
difficult, especially in humans. Our goal was to develop an in vitro model to study the regulation of 
CYP3A in enterocytes. To this end, we defined culture conditions under which adult rat jejunal explants 
maintained viable appearing villi for 21 hr. When dexamethasone, the prototypical inducer of CYP3Al 
in rat hepatocytes, was added to the culture medium, there was a time-dependent induction of CYP3Al 
mRNA and CYP3A protein in explant enterocytes which was essentially indistinguishable from the time 
course of induction of CYP3Al mRNA and protein in enterocytes in uiuo. This effect of dexamethasone 
appeared to be specific since dexamethasone had no consistent effect on the explant concentration of 
another enterocyte specific mRNA, intestinal fatty acid binding protein. Using this explant culture 
model, we found that CYP3Al mRNA was also inducible by clotrimazole but we were unable to detect 
induction by rifampicin or troleandomycin. Our observations suggest that jejunal explants may provide 
an appropriate model for the study of the regulation of CYP3A and other drug-metabolizing enzymes. 
The cytochromes P450 (P450st) are a gene 
superfamily of heme-containing enzymes responsible 
for the oxidative metabolism of xenobiotics, including 
many important medications (reviewed in Refs. l- 
3). P45Os are most abundant in the liver where their 
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$ Complimentary DNAs corresponding to two genes 
(CYP3Al and CYP3A2) have been cloned and sequenced 
from a rat liver cDNA library [5]. It seems likely that 
additional CYP3A eenes exist because aonroximatelv 90 Kb 
of rat genomic DNA hybridize with a Ci’P3A cDNA under 
low stringency conditions [5] and just 30 kb of this can be 
accounted for by the CYP3AI gene (John Schuetz, personal 
communication, cited with permission). Moreover, three 
proteins that appear to belong to the CYP3A family have 
been purified from rat liver [6] and up to four distinct 
proteins immunochemically related to purified CYP3A 
proteins have been detected on immunoblots of liver 
microsomes f7,8]. In aggregate, these observations suggest 
that the CYPjA gene fr&l$s probably not large; CYPjk, 
CYP3A2 and probablv one or two additional unidentified 
genes are expressed in-rat liver. In rat enterocytes. we have 
shown that the CYP3A protein(s) present in enterocytes 
obtained from untreated rats is unlikely to be the product(s) 
of the CYP3AI or CYP3A2 genes and presumably reflects 
expression of the unidentified gene(s) [8). 
regulation has been studied extensively. The P45Os 
that have been implicated most frequently in the 
hepatic metabolism of xenobiotics belong to three 
families, each comprised of proteins that share 
greater than 40% amino acid sequence homology 
(41. One family (termed CYPl) contains two highly 
homologous proteins that are inducible by 2,3,7,8- 
tetrachlorodibenzo-p-dioxin (TCDD) and some 
arylhydrocarbons. The second family (CYP2) is 
complex and includes the major phenobarbital- 
inducible P45Os (CYP2Bl and CYP2B2) and the 
major ethanol-inducible P450 (CYP2El). 
We have been most interested in a group of 
enzymes within the third P450 family which share 
greater than 65% amino acid sequence homology 
and are termed the CYP3A$ subfamily. In the liver, 
CYP3A enzymes are inducible by dexamethasone 
and for this reason CYP3A enzymes have been 
called the “glucocorticoid-inducible” P45Os [7,9- 
11]. However, CYP3A enzymes have been shown 
to also be inducible in the liver by many structurally 
diverse compounds, including a number of commonly 
used medications [7,9-131. Cultured primary hepa- 
tocytes retain responsiveness to many CYP3A 
inducers and therefore provide a valid in vitro model 
for the study of CYP3A regulation [13-171. The use 
of cultured hepatocytes has greatly facilitated the 
characterization of the regulation of hepatic CYP3A 
in a variety of mammals, including humans [13]. 
CYP3A enzymes are also abundant in rat and 
human enterocytes [18,19]. We have shown 
previously that when rats are treated with dex- 
amethasone, there is induction of CYP3A protein 
and CYP3Al mRNA in jejunal enterocytes [18,20]. 
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We have also shown that the antibiotic rifampicin, 
which induces CYP3A enzymes in human liver, 
induces CYP3A protein and CYP3A4 mRNA in 
human small bowel enterocytes [19]. However, it is 
not known whether enterocytes respond to other 
inducers of liver CYP3A enzymes. This is likely to 
be a clinically important question because we have 
shown that in both rats and humans CYP3A within 
small bowel enterocytes can catalyze significant “first 
pass” metabolism of some orally administered 
medications [20,21]. Induction of enterocyte CYP3A 
enzymes results in increased “first pass” metabolism 
of orally administered substrates in rats and it seems 
likely that this is also the case in humans [19,21- 
231. Induction of enterocyte CYP3A could therefore 
reduce the oral bioavailability of CYP3A substrates 
including dihydropyridine calcium channel antag- 
onists [24], immunosuppressives [25], and dietary 
contaminants such as aflatoxin Bi [26]. 
It would be difficult to study regulation of CYP3A 
enzymes in enterocytes in vivo, particularly in 
humans. It would obviously be desirable to have an 
in vitro model suitable for these studies. We here 
present data that suggest that cultured explants of 
jejunum may provide such a model. 
METHODS 
The animal studies performed were in compliance 
with NIH guidelines for the use and care of laboratory 
animals and were approved by the University 
Committee on Use and Care of Animals of the 
University of Michigan. 
In vivo studies 
Animals and treatments. Female Sprague-Dawley 
rats weighing 175-200 g were obtained from Charles 
River Laboratories (Portage, MI) and housed in 
wire-bottom cages. The animals had free access to 
tap water and standard laboratory chow until 
dexamethasone (Sigma Chemical Co., St. Louis, 
MO), 80 mg/kg, was administered in 1 mL corn oil 
by intraperitoneal injection; then the food was 
removed but access to water continued ad lib. 
Enterocyte isolation. Each rat was given light ether 
anesthesia prior to decapitation. A 20-cm segment 
of jejunum beginning 2 cm distal to the ligament of 
Treitz was excised. Enterocytes were isolated from 
the jejunal segment by calcium chelation [27,28]. 
Light microscopy of tissue sections revealed that the 
enterocytes along the entire length of the villi, but 
not crypt cells, were harvested. Because of the 
relative instability of RNA, the method was modified 
when harvesting enterocytes for RNA isolation by 
using room temperature rather than 37” solutions. 
Microsome preparation. Microsomes were pre- 
pared from the harvested enterocytes by the calcium 
precipitation method of Bonkovsky et al. [28] with 
themodificationthatcelldisruptionwasaccomplished 
by sonication using a Sonifier Cell Disruptor (Heat 
Systems/Ultrasonics, Farmingdale, NY) at setting 
100 for 10 sec. 
Protein assay. The protein concentrations of the 
microsomal samples were measured by the method 
of Lowry as modified by Schacterle and Pollack [29]. 
Western immunoblots. Immunoblots were pre- 
pared as previously described [30]. CYP3A proteins 
were detected using a monoclonal antibody named 
13-7-10 [31] at a concentration of 0.024 mg protein/ 
mL. This antibody recognizes CYP3A proteins 
present in rat liver and small bowel enterocytes 
[18,30]. (The 13-7-10 antibody was a gift from Dr. 
Pierre Kremers, Laboratoire de Chimie Medicale, 
Institut de Pathologie, Universite de Liege, Liege, 
Belgium.) 
RNA isolation. After pelleting the enterocytes by 
centrifugation at 900 g at 4” for 5 min and aspirating 
and discarding the Solution B (2.7 mM KC1/137 mM 
NaCl/1.47 mM KHzP04/8.1 mM Na2HP04/1.5 mM 
EDTA/O.S mM dithiothreitol/0.23 mM phenyl- 
methylsulfonyl fluoride) [27,28], the cells were 
dispersed by vortexing in 10 mM Tris-HC1 ( pH 7.4)/ 
4 M guanidine isothiocyanate [32]/2% N-lauroyl- 
sarcosine (sodium salt)/1 M 2-mercaptoethanol and 
then stored at -80”. At a convenient later time, 
each sample was thawed rapidly at 65”, drawn twice 
through a 23-gauge needle, layered over a 5.7 M 
cesium chloride cushion [33], and then centrifuged 
at 32,OOOrpm overnight in a Beckman L8-70M 
ultracentrifuge (Beckman Instrument Co., Arlington 
Heights, IL) using an SW41 swinging bucket rotor. 
The resulting pellet was washed twice with absolute 
ethanol, then redissolved in diethylpyrocarbonate 
(DEPC)-treated water while heating to 60” for 5 min. 
A l/10 volume of 3 M sodium acetate (pH 5.0) and 
3 volumes of cold absolute ethanol were added and 
mixed, and the sample was placed at -80” for at 
least 1 hr. RNA was pelleted by centrifugation at 
10,OOOg at 4” for 10 min. The pellet was dried and 
then dissolved in DEPC-treated water. RNA 
concentrations were measured using absorbance at 
260 nm. The polymerase chain reaction was carried 
out as described below for in vitro studies. 
In vitro studies 
Animals. Female Sprague-Dawley rats (270- 
315 g) were obtained from Charles River Lab- 
oratories and housed in wire-bottom cages. The 
animals had free access to tap water and standard 
laboratory chow. 
Surgery. Each rat was given light ether anesthesia 
prior to decapitation. A segment of jejunum 5 20 cm 
in length was excised beginning 1 cm distal to the 
ligament of Treitz. The jejunal segment was placed 
immediately in a sterile petri dish on ice which 
contained 80% CMRL Medium 1066/20% F-12 
(Ham) Nutrient Mixture that had been supplemented 
with glucose to a final concentration of 25 mM and 
that had been equilibrated with 95% Or/5% C02. 
A portion of this medium was used to gently flush 
debris from the lumen of the segment. Sterile scissors 
were used to cut open the jejunal segment lengthwise 
and, beginning just distal to the first 1 cm which was 
discarded, 2-3 mm wide full thickness strips 
(weighing approximately 40mg each) were cut off 
and placed in culture. As 0-hr specimens, one strip 
was placed in neutral buffered formalin and another 
indenaturingsolution (4 Mguanidineisothiocyanate/ 
25 mM sodium citrate (pH 7.0)/0.5% (w/v) N- 
lauroylsarcosine) [34]. The latter strip was hom- 
ogenized with a conical glass tissue grinder and 
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stored at -80” pending further processing (see “RNA 
i.sofation” below). 
Culture conditions. The jejunal explants were 
cultured by the method of Browning and Trier [35] 
but using a different medium. In our hands, CMRL 
Medium 1066 (as used by Autrup et al. [36] for rat 
colon explant cultures) has been superior to Trowell’s 
T8, L15, Medium 199, and Dulbecco’s Modified 
Eagle Medium (DMEM), and equal or superior to 
RPM1 1640 in supporting the viability and 
maintaining the differentiation of adult rat jejunal 
enterocytes in explant cultures. We have found no 
benefit in adding HEPES (10 or 25 mM) or tricine 
(10 or 50,uM) buffers, 5 mM galactose, 5 mM 
pyruvate, 5 nM ammonium vanadate, the oxygen 
carriers heptacosafluorotributylamine (2%, 4%, or 
lo%, v/v) or perfluorotributylamine (as FC-43 
Emulsion; Green Cross Corp., Osaka, Japan), or 
rat bile (O.l%, 0.2%, or 0.4%, v/v) to the medium. 
For the experiments described, the culture medium 
was composed of 8 parts CMRL Medium 1066 
(Gibco BRL, Grand Island, NY) + 2 parts F-12 
(Ham) Nutrient Mixture (Gibco BRL), combined 
and then supplemented to the indicated final 
concentrations with the following: fetal bovine serum 
(Hyclone, Logan, UT), 10%; glucose (Abbott 
Laboratories, North Chicago, IL), 25 mM; L- 
glutamine (Gibco BRL), 2 mM; ferrous sulfate 
(Sigma), 5 PM; sodium selenite (Sigma), 0.1 PM; 5- 
aminolevulinic acid (Sigma), 100 yM; zinc sulfate 
(Sigma), 3 PM; menadione sodium bisulfite (Sigma), 
145 nM; DL-cu-tocopherol (Gibco BRL), 45 nM; 
retinol acetate (Gibco BRL), 152nM; sodium 
penicillin G (Gibco BRL), lOOU/mL; and strep- 
tomycin sulfate (Gibco BRL), 100 yg/mL. All 
components used to supplement the medium were 
of cell culture quality. We have found recently that 
discontinuing supplementation with retinol acetate 
may be associated with less enterocyte de- 
differentiation. 
Medium (2.3 mL) was placed in the inner well of 
a polystyrene organ culture dish (Falcon, Oxnard, 
CA). A sterile stainless steel screen was placed on 
the ledge of the inner well and was submerged in 
the upper medium. Sterile normal saline was placed 
in the outer well. The dishes were placed in an air- 
tight jar that was gassed for 20min with 95% O,/ 
5% CO* at 1700cc/min, theoretically providing 
nearly 14 volume exchanges of gas. The jar was then 
sealed and a minimum of 40 additional min was 
allowed to elapse so that the medium could 
equilibrate with the new atmosphere. 
While the animal was being anesthetized, the 
culture dishes were removed from the jar and placed 
on ice. Surgery was performed as described above 
and each full thickness jejunal strip was placed 
villous side up on the stainless steel screen in an 
organ culture dish (one explant per dish). The 
explanted tissue was not fully submerged, but 
medium was observed to be drawn between and 
over the villi by capillary action. The cultures were 
maintained on ice until all were obtained. The dishes 
were then returned to the air-tight jar that was 
gassed for 20 min and sealed. The start of gassing 
occurred 15-20 min after decapitation of the rat and 
was considered 0 hr. The jar was placed on a rotating 
table at 40rpm in a 37” incubator. The constant 
agitation produced by the rotating table appeared 
to minimize the adherence to the villi of sloughed 
enterocytes and generally improved the viability of 
the explants. 
Treatments. Paired jejunal explants from a single 
rat were exposed throughout the 18 to 21-hr culture 
period to dexamethasone (Sigma) or, in the final 
study, other compounds believed to induce CYP3A 
in hepatocytes [7,10-131: spironolactone (Sigma); 
phenobarbital (Spectrum Chemical Co., Gardena, 
CA); y-chlordane (gift from the Velsicol Chemical 
Corp., Chicago, IL); troleandomycin (“tri- 
acetyloleandomycin”; gift from Pfizer Laboratories, 
Brooklyn, NY); rifampicin (Sigma); ketoconazole 
(Sigma; discontinued 10/91); clotrimazole (Sigma); 
or isosafrole (Aldrich Chemical Co., Milwaukee, 
WI). A lo-*M solution of each compound was 
prepared in dimethyl sulfoxide. Each solution was 
then diluted 1:lOOO in culture medium, resultin in 
a final concentration of test compound of lo- B M. 
This concentration has been used previously in 
primary cultures of rat hepatocytes when screening 
for induction of CYP3A enzymes [14,16,37]. 
Control cultures were exposed to vehicle alone 
(dimethyl sulfoxide) diluted 1:lOOO in culture 
medium. At the end of the culture period, one 
explant from each pair was placed in neutral buffered 
formalin and the other was placed in denaturing 
solution [34], homogenized in a conical glass tissue 
grinder, and stored at -80” pending further 
processing (see “RNA isolation” below). For the 
studies examining the time course of response to 
dexamethasone, the jar was regassed for 20 min after 
removal of each time point’s explants, and then 
sealed and returned to the rotating table in the 
incubator. 
Immunohistochemistry. The explants, which had 
been placed in neutral buffered formalin at the end 
of the culture period, were embedded in parafin and 
4 pm thick sections were prepared. The monoclonal 
antibody (13-7-10) used to develop the Western blots 
(in uivo studies discussed above) failed to react with 
formalin fixed tissue. We therefore performed our 
immunohistochemistry using serial dilutions of a 
polyclonal rabbit anti-CYP3A3/4 antibody [38], 
which was a gift from Dr. Steven Wrighton, Eli Lilly 
Corp., Indianapolis, IN. We have previously 
characterized this antibody as selectively identifying 
CYP3A proteins in rat jejunal tissue sections using 
the identical immunohistochemical techniques [30]. 
Following a 20-min incubation with the primary 
antibody, the sections were sequentially incubated, 
with intervening washes in phosphate-buffered saline 
(PBS), with the following reagents (Histostain-SP 
kit, Zymed Laboratories, South San Francisco, CA): 
biotinylated goat anti-rabbit IgG (H&L) for 20 min, 
horseradish peroxidase conjugated streptavidin for 
15 min, hydrogen peroxide/aminoethylcarbazole for 
3.5 min. All incubations were carried out at room 
temperature. Sections were then counterstained with 
hematoxylin. A single observer (W.O.D.), who was 
blinded to the culture conditions, assessed the 
intensity of the staining of each section. Serial 
dilutions of the primary antibody were used to study 
sections from each of the explants but the 1:750 
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dilution appeared to give the widest range of staining have the exact nucleic acid sequence predicted by 
intensities between treatments. the published cDNA sequences [5,41]. 
RNA bolation. RNA was isolated from the entire 
explants by the method of Chomczynski and Sacchi 
[34]. Having an estimated weight of 4Omg, each 
explant was placed in 400 PL of denaturing solution 
[34], homogenized in a conical glass tissue grinder 
with ground glass pestle, and then stored at -80”. 
At a convenient later time, the solution was thawed 
quickly at 65” and processed according to the 
published protocol, adjusting reagent volumes 
proportionately as appropriate for the initial 400 PL 
volume. 
Polymerase chain reaction. The polymerase chain 
reaction has been shown to be capable of quantitating 
multiple RNA species present in low abundance in 
small amounts of tissue [39,40]. This appeared to 
be an ideal technique for application to jejunal 
explants where enterocytes represent a small 
proportion of the total cell population. cDNA was 
prepared from each RNA sample by incubating 1 pg 
total RNA at 41” for 1 hr with 35 U of reverse 
transcriptase (from avian myeloblastosis virus; 
Seikagaku America, St. Petersburg, FL) in a 50- 
PL reaction mixture containing 50 mM Tris- 
HCl (pH 8.3), 50 mM potassium chloride, 10 mM 
dithiothreitol, 13 PM oligo (12-18) dT, and 0.5 mM 
each dATP, dTTP, dGTP, and dCTP. 
The polymerase chain reaction (PCR) was 
performed on each explant cDNA preparation. We 
used as primers 30-mer synthetic oligonucleotides 
recognizing characteristic regions of the cDNAs of 
CYP3Al (sense primer, bases 1368-1398; anti-sense 
primer, bases 1618-1648; [5]) or rat intestinal fatty 
acid binding protein (IFABP; sense primer, bases 
4-34; anti-sense primer, bases 3704; [41]). To 
make amplification of genomic DNA distinguishable 
should it occur, the primers were chosen so that 
the amplified segments spanned an intron. The 
polymerase chain reaction was carried out in a total 
volume of 50 yL containing 10 PL of an enterocyte 
cDNA preparation and the following final con- 
centrations of reagents: 10 mM Tris-HCI (pH 8.3), 
50 mM potassium chloride, 1.6 mM magnesium 
chloride, 2 mM dithiothreitol, 0.01% gelatin, 3.5 to 
4.5 U Thermus aquaticus (Taq) DNA polymerase 
(Beckman, Arlington Heights, IL), 2pM each 
oligonucleotide primer, and 0.1 mM each dATP, 
dlTP, dGTP, and dcTP. 
To determine conditions under which the intensity 
of ethidium staining of amplified bands reflected 
tissue concentrations of the target mRNAs, RNA 
prepared from a jejunal explant was serially diluted 
with RNA prepared from rat heart (a tissue that did 
not contain detectable CYP3Al or IFABP mRNAs). 
The RNA mixtures were then reverse transcribed 
into cDNAs and subjected to PCR using synthetic 
oligonucleotide primers specific for CYP3Al or 
IFABP cDNA. We found that under the PCR 
conditions described above, the band intensity on 
ethidium stained gels diminished appropriately as 
the concentration of specific mRNA decreased in 
the samples (Fig. 1). This result was easily reproduced 
for IFABP but less easily for CYP3Al for which 
higher numbers of PCR cycles were required to 
visualize a band. Minute differences in the efficiency 
of amplification can result in significant increases or 
decreases in the quantity of amplified cDNA, and 
disparities can be expected to increase as cycle 
number increases. However, we found that our 
results became quite reproducible when reactions 
were run in parallel using a single stock solution 
(40 pL) that contained all reagents except the cDNA 
sample to be assayed. We have analyzed enterocyte 
RNA samples simultaneously by this PCR technique 
and on Northern blots probed with a CYP3Al- 
specific 30-mer synthetic oligonucleotide under 
conditions reported to selectively identify CYP3Al 
mRNA [5]. The relative staining intensity of PCR 
products on the ethidium stained gels essentially 
mirrors the relative intensities of the hybridization 
signals on the Northern blots (data not shown). 
Nonetheless, the results of our PCR analyses must 
be considered semiquantitative in the absence of 
internal standards for amplification efficiency. All 
PCR amplifications were repeated at least twice, 
and representative ethidium stained gels are shown. 
RESULTS 
Time course of induction of CYP3A in vivo 
PCR was carried out in a DNA Thermal Cycler 
(Perkin-Elmer Cetus, Norwalk, CT/Emeryville, 
CA) at conditions of (94” for 45 set, 72” for 1 min 
15 set) x 34 cycles for CYP3Al or 22 cycles for 
IFABP, followed by a final extension step at 72” 
for 10min. The products were subjected to 
electrophoresis in 1% agarose (Gibco BRL)/2% 
NuSieve (FMC BioProducts, Rockland, ME)/0.04 M 
T&-acetate, 0.001 M EDTA, pH 8.0 (TAE) gels in 
TAE buffer and stained with ethidium bromide to 
visualize the amplified fragments of CYP3Al or 
IFABP cDNA (280 and 396 bp in size, respectively). 
We have shown previously ([30] and unpublished 
data) that when cDNA prepared from rat enterocytes 
is subjected to amplification under these conditions, 
the fragments of cDNA amplified with the CYP3Al 
(detectable only in induced rats) and IFABP primers 
We have shown previously that when rats are 
treated with dexamethasone for 2 days, there is 
induction of CYP3A protein and CYP3Al mRNA 
in enterocytes [30]. To determine the time course of 
induction, we treated a group of rats with a single 
dose of dexamethasone and killed them at various 
times after treatment. Mature enterocytes were 
harvested and the microsomal fraction was prepared 
as described in Methods. We were unable to detect 
an increase in the microsomal content of CYP3A 
protein prior to 6 hr after intraperitoneal treatment 
and the concentration appeared to peak by 18 hr 
(Fig. 2). In rats given the identical dose of 
dexamethasone by oral gavage, the time course of 
induction of CYP3A protein appeared to be identical 
(data not shown). 
CYP3Al mRNA was undetectable in enterocytes 
from uninduced animals as we have reported 
previously [30]. CYP3Al mRNA became detectable 
by our PCR technique (see Methods) within 3-6 hr 
after intraperitoneal injection of dexamethasone 
(Fig. 3, top panel). This is similar to the time course 
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1:l 1:2 1:4 1:8 1:16 Hrt Rgt MW 
Rgt Std 1:l 1:2 1:4 1:8 1:16 Hrt 
Fig. 1. Quantitation of CYP3Al mRNA and intestinal fatty acid binding protein (IFABP) mRNA using 
the polymerase chain reaction (PCR). Total RNA obtained from enterocytes was diluted in the 
proportions indicated with RNA obtained from rat heart. The RNA mixtures were then reverse 
transcribed into cDNA and subjected to PCR using 30-mer synthetic oligonucleotide primers 
corresponding to characteristic regions of the CYP3Al cDNA (top panel) or IFABP cDNA (bottom 
panel) as described in Methods. Abbreviations: Rgt, reagent mixture alone without cDNA added; Std 
or MW, molecular weight standards; and Hrt, heart cDNA. 
of induction of CYP3Al mRNA in the liver after present in the small bowel wall [43], a distribution 
an intraperitoneal dose of dexamethasone [42]. As similar to that of CYP3A protein [18,30]. The 
a control, we determined the relative content of concentration of IFABP should, therefore, reflect 
IFABP mRNA in each RNA sample using a differences in the relative proportions of mature 
semiquantitative PCR technique (see Methods). enterocytes obtained from each rat. In contrast to 
IFABP is abundant in villous tip enterocytes but is the induction of CYP3Al mRNA in response to 
virtually absent from crypt cells or other cell types dexamethasone. the enterocyte content of IFABP 
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0 1 3 6 12 18 24 
Time after DEX dose (hours) 
Fig. 2. Time course of induction of enterocyte CYP3A protein after a single intraperitoneal injection 
of dexamethasone (DEX). Adult female rats received 80 mg/kg DEX as a single intraperitoneal dose 
(time 0). Two rats were killed at each of the indicated time points and microsomes were prepared from 
the pooled jejunal enterocytes. The microsomal proteins (5 &lane) were separated on 10% 
polyacrylamide gels containing 0.1% sodium dodecyl sulfate (SDS) and then electrophoretically 
transferred to nitrocellulose sheets. The blots were incubated with a monoclonal antibodv 113-7-10) 
that selectively recognizes CYP3A proteins. Antigen-antibody reaction was visualized using a’peroxidase 
conjugated secondary antibody and 3,3’-diaminobenzidine tertrahydrochloride. This experiment was 
performed once. 
mRNA did not increase, but instead appeared 
to transiently decrease, after treatment with 
dexamethasone (Fig. 3, bottom panel). 
Explant studies 
Considering the above in vivo data (Figs. 2 and 
3), it would be necessary to maintain enterocytes ex 
vivo for at least 12 hr in order to achieve our goal 
of developing an in vitro enterocyte model suitable 
for studying CYP3Al regulation. We defined 
conditions (outlined in Methods) under which full 
thickness adult rat jejunal explants survived in 
culture for at least 18 hr. Although these explants 
showed dramatic morphologic changes over time in 
culture (Fig. 4), with loss of crypts by approximately 
8 hr, viable appearing villous structures persisted to 
21 hr. Enterocyte loss over time appeared to be 
disproportionately greater than loss of cells from the 
lamina propria. There was also a tendency toward 
enterocyte de-differentiation as judged by loss of 
cell height (Fig. 4) and contraction of the apical 
microvilli (Fig. 5). 
To determine whether the jejunal explants 
remained responsive to dexamethasone, explants 
from nine rats were placed in medium containing 
either dexamethasone or vehicle alone (dimethyl 
sulfoxide) for 21 hr. The presence of dexamethasone 
in the medium did not appear to improve enterocyte 
differentiation as judged by electron and light 
microscopy (Figs. 5 and 6). However, immu- 
nohistochemical staining with anti-CYP3A3/4 indi- 
cated that enterocyte CYP3A protein had been 
induced in the presence of dexamethasone. In every 
case, an investigator blinded to the treatments 
judged the staining to be more intense in the explants 
exposed to dexamethasone than in control or 0 hr 
explants from the same rat. There was also an 
increase in the number of enterocytes exhibiting 
immunoreactivity as compared to either control 
cultures or the 0 hr tissue from the same rat 
(representative sections are shown in Fig. 6). In 
most instances, the control explants stained somewhat 
less intensely than did 0-hr tissue. 
We next examined whether CYP3Al mRNA was 
also induced in explants by dexamethasone. In 
control explants from some rats, CYP3Al mRNA 
became detectable by PCR between 12 and 16 hr in 
culture, but then decreased, and was usually no 
longer detectable by 20 hr (Fig. 7, top panel). In 
dexamethasone-treated explants, CYP3Al mRNA 
was detectable as early as 4 hr in culture in some 
rats. The concentration of CYP3Al mRNA then 
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Fig. 3. Time course of induction of enterocyte CYP3Al mRNA after a single intraperitoneal injection 
of dexamethasone. Adult female rats received 80 mg/kg dexamethasone as a single intraperitoneal dose 
(time 0). Three rats were killed at each of the indicated time points, and total RNA was prepared from 
the pooled jejunal enterocytes. The RNA was reverse transcribed into cDNA and subjected to the 
semiquantitative PCR technique using oligonucleotide primers specific for CYP3Al (top panel) and 
IFABP (bottom panel) cDNAs. The PCR reaction products were electrophoresed on 1% agarose/2% 
NuSieve gels, stained with ethidium bromide, and the amplified bands were visualized by UV 
transillumination. The relative intensities of the ethidium stained bands on the gels reflect the relative 
concentrations of the target mRNAs present in the original RNA samples (Fig. 1, Methods). 
Abbreviations: 24C, control animal given intraperitoneal injection of vehicle (corn oil) alone; and Rgt, 
reagents alone without cDNA. This experiment was performed three times, with three rats per time 
point in each experiment. 
progressively increased throughout the remaining 
time in culture (Fig. 7, top panel). Whenever 
CYP3Al mRNA was at a detectable level, the 
concentration observed in dexamethasone-treated 
explants was always greater than that measured in 
the corresponding control explants. The content of 
IFABP mRNA (Fig. 7, bottom panel) progressively 
decreased over time in culture, consistent with the 
disproportionate loss of enterocytes as compared 
with other cell types within the explant (Fig. 4). The 
presence of dexamethasone in the medium had no 
consistent effect on the level of IFABP mRNA (Fig. 
7, bottom panel). 
The above studies demonstrated that enterocytes in 
the explants remained responsive to dexamethasone. 
To further evaluate the usefulness of this model, we 
next exposed jejunal explants prepared from single 
rats to a variety of compounds believed to 
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Fig. 4. Light microscopy of jejunal explants maintained in culture for up to 21 hr. Full thickness biopsies 
of rat jejunum were cultured under conditions described in Methods. Explants were removed from 
culture at the indicated time points, fixed in formalin, embedded in paraffin, sectioned, and stained 
with hematoxylin and eosin. Magnification: x94. This experiment was performed four times with 
explants obtained from four different rats. 
induce CYP3A in liver [7,10-131, in addition to 
dexamethasone. This experiment was performed in 
four different rats. The general viability and degree 
of maintenance of differentiation of enterocytes 
varied from culture to culture and from rat to rat, 
as judged by light microscopy (not shown). However, 
none of the compounds in the battery appeared to 
have a consistently beneficial or harmful effect on 
enterocyte viability or morphology. 
The relative concentrations of CYP3Al mRNA 
and of IFABP mRNA were determined in the 
explants treated with each potential inducer. 
Representative gels from electrophoresis of PCR 
products are shown in Fig. 8, top and bottom panels, 
respectively. An unequivocal increase in CYP3Al 
mRNA (as compared with the level in the control 
explant from the same rat) was seen in the 
dexamethasone- or clotrimazole-treated explants 
0 hour 18 h CONTROL 18 h DEX 
Fig. 5. Electron microscopy of enterocytes in the cultured explants. Jejunal explants were maintained 
in culture for 18 hr and then fixed in l/2 strength Karnovsky’s fixative, postfixed in osmium, embedded 
in epoxy resin, sectioned, and stained with uranyl magnesium acetate and with lead citrate. Magnification: 
~21,000. This was done once on explants from one rat. 
21 h DEX 
Fig. 6. Immunoreactive CYP3A protein in control and dexamethasone-treated explants. Jejunal explants 
were incubated in medium containing dexamethasone (DEX, 10e5M) or vehicle (CONTROL; dimethyl 
sulfoxide) for 21 hr. The explants were then fixed in formalin, embedded in paraffin, sectioned, and 
incubated with various dilutions of anti-CYP3A3/4 IgG or pre-immune serum. Antibody reactivity 
(dark black) was visualized by sequential incubations with biotinylated secondary antibody, peroxidase 
conjugated streptavidin, and H,O,/aminoethylcarbazole. Magnification: x 120. This experiment was 
performed nine times with explants from nine different rats. 
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Fig. 7. Time course of induction of CYP3Al mRNA (top panel) and IFABP mRNA (bottom panel) 
in cultured explants of jejunal mucosa. Explants were removed from culture at various times after the 
start of incubation in medium containing dexamethasone or vehicle alone (dimethyl sulfoxide). Total 
RNA was extracted from the entire explant, reverse transcribed into cDNA, and subjected to the 
semiquantitative PCR technique using oligonucleotide primers specific for CYP3Al (top) and IFABP 
(bottom) cDNAs as described in Methods. The reaction products were subjected to electrophoresis on 
1% agarose/2% NuSieve gels, stained with ethidium bromide, and the amplified bands were visualized 
by UV transillumination. Abbreviations: C, control (vehicle alone); D, dexamethasone treated; MW, 
molecular weight standards; and Rgt, reagents alone without cDNA. This experiment was performed 
twice with explants from two different rats. 
prepared from each of the four rats. Induction was 
observed in three of the four explants treated with 
spironolactone or y-chlordane, and in two of the 
four explants treated with ketoconazole or isosafrole. 
No induction of CYP3Al mRNA was seen in any 
explants treated with phenobarbital, rifampicin, or 
troleandomycin as compared with controls. In 
contrast, there was little variation in the level of 
IFABP mRNA among the treatment groups, with 
none of the compounds having a consistent effect. 
DISCUSSION 
The goal of our studies was to develop an in vitro 
model suitable for studying regulation of CYP3A 
enzymes in enterocytes. Our in viuo studies suggested 
that it would be necessary to maintain enterocytes 
ex uivo for at least 12 hr to study induction in 
response to dexamethasone. Isolated adult rat 
enterocytes in suspension culture remain viable for 
only several hours [44) and were therefore excluded 
280 bp 
396 bp 
Induction of CYP3A in enterocytes 
Ohr VEH CHL PB DEX SPN RIF TAO KET CL0 IS0 Cl C2 MW Rgt 
Ohr V”;H CHL PB OEX SPN RIF TAO KET CL0 IS0 Cl C2 Rgt MW 
Fig. 8. Induction of CYP3Al mRNA in cultured jejunal explants exposed to various known inducers 
of hepatic CYP3A enzymes. Explants prepared from single rats were cultured for 18-21 hr in the 
presence of each of the indicated compounds. Total RNA was extracted from the entire explant, reverse 
transcribed into cDNA, and subjected to the semiquantitative PCR technique using oligonucleotide 
primers specific for CYP3Al (top panel) and IFABP (bottom panel) cDNAs as described in Methods. 
The reaction products were subjected to electrophoresis on 1% agarose/t% NuSieve gels, stained with 
ethidium bromide, and the amplified bands were visualized by UV transillumination. Abbreviations: 
VEH, vehicle (dimethyl sulfoxide); CHL, y-chlordane; PB, phenobarbital; DEX, dexamethasone; 
SPN, spironolactone; RIF, rifampicin; TAO, troleandomycin; KET, ketoconazole; CLO, clotrimazole; 
ISO, isosafrole; Cl, explant treated with pyrazole (an inducer of CYP2El); C2, cDNA from jejunal 
scrapings from a dexamethasone-treated rat; MW, molecular weight standards; and Rgt, reagents alone 
without cDNA. This experiment was performed four times with explants from four different rats. 
from consideration. Epithelioid cells or cell lines can antigenic characteristics of differentiated villous 
be derived from “outgrowths” from explanted fetal enterocytes [44] and retain some features of crypt 
rat intestinal tissue that is maintained in culture for or fetal enterocytes [46]. 
lengthy periods. These cells may develop certain Several investigators have cultured full thickness 
differentiated structural features (e.g. microvilli [44- biopsies of jejunum from several mammalian species 
461) or functions (e.g. expression of alkaline including humans for greater than 24 hr with 
phosphatase 1451). However, these cells lack certain preservation of morphological features. To our 
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knowledge, however, there have been no previous 
reports of prolonged maintenance in culture of 
jejunal explants from adult rat which appear to be 
more difhcult to maintain in culture than are jejunal 
explants obtained from other species 1471. Some 
investigators have had success culturing explants of 
fetal or suckling rat intestine. However, use of fetal 
tissue poses a problem when studying the regulation 
of CYP3A genes since these genes have complex 
developmental regulation, at least in liver [48]. 
We were able to define culture conditions under 
which adult rat jejunal explants maintained viable 
appearing villi for 21 hr, although the absolute 
number of viable enterocytes decreased with time 
in culture (Fig. 4). Total P450 levels were not 
evaluated in the explants, but we supplemented our 
medium with some of the elements and compounds 
that others have found to be important in maintaining 
P450 Ievels in primary cultures of rat hepatocytes: 
selenium [49]; 5-aminolevulinic acid [SO, 511; and 
zinc [52]. The major disadvantage of explants is that 
enterocytes represent only a fraction of the total 
cells present (Fig. 4) and, therefore, CYP3A protein 
and mRNA are greatly diluted when the whole 
explant is processed. Indeed, it would be impossible 
to detect CYP3A protein or mRNA in the explants 
using standard immunoblot and Northern blot 
techniques, respectively. We therefore approached 
this problem by using immunohistochemistry and a 
semiquantitative PCR technique. 
We found that dexamethasone treatment of 
explants resulted in induction of CYP3A protein in 
the villous enterocytes as judged by blinded 
interpretation of tissue sections incubated with anti- 
CYP3A IgG (Fig. 6). Dexamethasone also resulted 
in a time-dependent induction of CYP3Al mRNA 
(Fig. 7, top panel) that was essentially indis- 
tinguishable from our observations in enterocytes in 
vivo (Fig. 3, top panel). Since even our highly 
sensitive PCR technique could not detect CYP3Al 
mRNA in control enterocytes, it seems likely that 
induction of enterocyte CYP3Al mRNA by 
dexamethasone involves transcriptional activation, 
as is the case in liver [42]. However, weak induction 
of CYP3Al mRNA was also detectabie in explants 
at early time points in the control medium (Fig. 7, 
top panel), suggesting transient transcriptional 
activationof the CYP3AI gene. Therefore, wecannot 
entirely exclude the possibility that accumulation of 
CYP3Al mRNA in the dexamethasone-treated 
explants was the result of mRNA stabilization rather 
than transcriptional activation of the corresponding 
gene. Post-transc~ptional induction of other P45Os 
has been shown to occur in hepatocytes in primary 
culture in the presence of dexamethasone [53]. 
However, dexamethasone did not cause an accumu- 
lation of all enterocyte mRNAs in our explants since 
it appeared to have no consistent effect on the 
concentration of IFABP mRNA in the explants 
(bottom panels of Figs. 7 and 8). 
Finally, we treated cultured jejunal explants with 
a battery of compounds that appear to induce 
CYP3A in liver. We found unequivocal induction of 
CYP3Al mRNA in each explant treated with 
dexamethasone or clotrimazole. Our data suggest 
that spironolactone, y-chlordane, ketoconazole, and 
isosafrole are also capable of inducing CYP3Al 
mRNA in the explants. In contrast, rifampicin, 
troleandomycin, and phenobarbital did not induce 
CYP3Al mRNA in any of the explants. The lack of 
response to ~fampicin is not surprising since this 
compound is not an inducer of CYP3A enzymes in 
rat liver (in distinction to rabbit and human liver) 
[lo, 541. Troleandomycin is an inducer of CYP3A 
protein and mRNA in rat liver but not in primary 
rat hepatocytes in culture [12]. It remains to be 
determined whether troleandomycin is an inducer 
of CYP3A enzymes in enterocytes in vivo. The 
absence of induction of enterocyte CYP3Al mRNA 
in the explants treated with phenobarbital may 
reflect the relatively low concentration ( low5 M) 
of phenobarbital used. Higher concentrations 
(2 x 10e3 M) of phenobarbital have been used to 
demonstrate induction of CYMA protein and 
CYP3Al mRNA in cutured hepatocytes 1171. 
In summary, explant culture of jejunal biopsies 
appears to be a promising en vivo system to study 
the regulation of CYP3A genes in enterocytes. We 
have been able to demonstrate dexamethasone 
induction of CYP3Al mRNA and CYP3A protein 
in explants and our results generally mirror the 
effects of dexamethasone in vivo. Our prelimina~ 
studies with other potential inducers suggest that 
enterocyte CYP3Al mRNA is inducible by other 
compounds known to induce this mRNA in 
hepatocytes. We believe that the techniques we 
present here can be readily adapted to studying 
regulation of other dNg-meta~l~ing enzymes in 
enterocytes. CYPl and CYP2 family members, for 
example, are also present and inducible in rat 
enterocytes [SS]. It should be possible to use 
PCR to simultaneously quantitate the mRNAs 
corresponding to these and to many other drug- 
metabolizing enzymes in explants. Finally, it should 
be possible to adapt our culture and assay techniques 
to obtain similar info~ation from duodenal biopsies 
that are routinely obtained from patients during 
endoscopic procedures. 
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